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NHS Trust, London, United KingdomABSTRACT The von Willebrand factor (VWF) and coagulation factor VIII (FVIII) are intricately involved in hemostasis. A tight,
noncovalent complex between VWF and FVIII prolongs the half-life of FVIII in plasma, and failure to form this complex leads to
rapid clearance of FVIII and bleeding diatheses such as hemophilia A and von Willebrand disease (VWD) type 2N. High-reso-
lution insight into the complex between VWF and FVIII has so far been strikingly lacking. This is particularly the case for the
flexible a3 region of FVIII, which is imperative for high-affinity binding. Here, a structural and biophysical characterization of
the interaction between VWF and FVIII is presented with focus on two of the domains that have been proven pivotal for mediating
the interaction, namely the a3 region of FVIII and the TIL’E’ domains of VWF. Binding between the FVIII a3 region and VWF
TIL’E’ was here observed using NMR spectroscopy, where chemical shift changes were localized to two b-sheet regions on
the edge of TIL’E’ upon FVIII a3 region binding. Isothermal titration calorimetry and NMR spectroscopy were used to charac-
terize the interaction between FVIII and TIL’E’ as well as mutants of TIL’E’, which further highlights the importance of the b-sheet
region of TIL’E’ for high-affinity binding. Overall, the results presented provide new insight into the role the FVIII a3 region plays
for complex formation between VWF and FVIII and the b-sheet region of TIL’E’ is shown to be important for FVIII binding. Thus,
the results pave the way for further high-resolution insights into this imperative complex.SIGNIFICANCE The complex between von Willebrand factor (VWF) and factor VIII (FVIII) is imperative for hemostasis,
and failure to form this complex leads to bleeding diatheses such as hemophilia A and vonWillebrand disease (VWD). The
FVIII a3 acidic region is shown to interact with VWF TIL’E’, and the a3 binding region is localized to two b-sheet regions on
the periphery of TIL’. Characterizations of the interaction between FVIII and mutants of VWF TIL’E’ further highlight the
importance of the b-sheet region for binding. The insight into VWF:FVIII complex formation facilitate the design of improved
hemophilia A treatments, whereas the analysis of VWD mutations provides a link between genetic pathology and clinical
phenotype to facilitate targeted management of patients with VWD.INTRODUCTION
The interaction between von Willebrand factor (VWF) and
coagulation factor VIII (FVIII) is essential to hemostasis.
In blood plasma, a tight, noncovalent complex is formed be-
tween VWF and FVIII (1,2), which serves to prolong the
half-life of FVIII and locates FVIII to the incipient platelet
plug. The interaction between FVIII and VWF is disrupted
when FVIII is activated by thrombin; however, if the inter-Submitted March 5, 2019, and accepted for publication July 8, 2019.
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creativecommons.org/licenses/by/4.0/).action is intrinsically destabilized, FVIII is rapidly and
prematurely cleared from the blood stream (3,4). This pre-
mature clearance of FVIII is caused by a lower affinity of
the FVIII:VWF complex and leads to the bleeding disorders
hemophilia A and von Willebrand disease (VWD). The
severity of these diseases underpins the importance of the
interaction between FVIII and VWF and, in turn, the impor-
tance of characterizing the structure of this complex at high
resolution.
Mature FVIII is a 2332 residue protein consisting of six
major domains, A1-A2-B-A3-C1-C2, as well as three acidic
linker regions a1, a2, and a3 (5) (Fig. 1 a). FVIII is divided
into a heavy chain (A1-a1-A2-a2-B) and a light chainBiophysical Journal 117, 479–489, August 6, 2019 479
ab
FIGURE 1 Domain architecture of (a) coagulation FVIII and (b) the VWF. Specific domains investigated in this study are colored green; that is, the acidic
a3 region of FVIII and the TIL’E’ (D’) domains of the VWF. Cleavage sites for thrombin and furin are shown with arrows, and the previously identified
binding regions between FVIII and VWF are colored red. To see this figure in color, go online.
Dagil et al.(a3-A3-C1-C2) (5). The heavy chain and, in particular, the
FVIII B-domain are not involved in the interaction with
VWF, whereas the FVIII light chain interacts with VWF
(1,6–15), and the FVIII a3 region has been shown to be
important for high-affinity binding (1,8,9,13–15). The FVIII
a3 region spans FVIII residues 1649–1689 and is highly
negatively charged. In addition, the FVIII a3 region harbors
two of the six posttranslationally sulfated tyrosine residues
in FVIII: Tyr1664 and Tyr1680. Whereas sulfation of
Tyr1664 is important for activation by thrombin, sulfation
of Tyr1680 has been shown to increase the affinity of FVIII
for VWF (15). FVIII is activated by thrombin cleavage (16),
which results in a heterotrimeric activated FVIII with the
FVIII B-domain and a3 region abscized, resulting in an
abrogation of the interaction with VWF. Thus, the impor-
tance of the FVIII a3 region in mediating the binding with
VWF is emphasized by the fact that the complex between
FVIII and VWF is disrupted upon thrombin activation and
loss of a3 (8).
VWF consists of repeats of homologous domains
(17,18) and is expressed with a propetide that is cleaved
off to form mature VWF (Fig. 1 b). Mature VWF is a
2050 residue protein starting with the VWF TIL’E’ do-
mains at Ser764 (17). A significant number of binding
studies have firmly established the N-terminal part of
mature VWF to be the main binding site for FVIII
(7,19–22). The location of VWD type 2N mutants sup-
ports these results, as this VWD subtype is characterized
by a quantitative deficiency of FVIII caused by mutations
in VWF that impair the interaction with FVIII (23,24).
The majority of VWD 2N mutations are found in the dy-
namic N-terminal VWF TIL’ domain (see e.g. [25–28]),
with only a single mutation found in the more ordered
VWF E’ domain and a minor subset outside the VWF
TIL’E’ domains (29,30). A representation of type 2N mu-
tations on the structure of TIL’E’ recently gave the first
structural insight into the major FVIII binding site on
VWF and suggested that sites within the TIL’ domain
are essential for mediating the high-affinity binding be-
tween VWF and FVIII (31).480 Biophysical Journal 117, 479–489, August 6, 2019A recent crystal structure has revealed the VWF
TIL’E’D3 assembly at high resolution (32), whereas nega-
tive stain electron microscopy (EM) and hydrogen-deute-
rium exchange mass spectrometry have recently revealed
the three-dimensional structure of FVIII in complex with
VWF TIL’E’D3 (11,33). From the structures, it is evident
that the VWF TIL’ domain interacts with the FVIII C1
domain, the VWF E’ domain bridges the VWF TIL’ and
D3 domains, whereas the VWF D3 domain interacts with
the FVIII C1 and C2 domains (33). This picture corresponds
well with previously published data showing that binding of
an antibody targeting FVIII C1 impairs the binding to VWF
(34) and that the FVIII C1 domain is essential for high-affin-
ity interaction with VWF (35). In addition to the structural
information deducible from EM, hydrogen-deuterium ex-
change experiments have shown that the FVIII a3 residues
Val1670-Asp1678 are protected upon complex formation
with VWF TIL’E’D3, thus indicating that residues in the
FVIII a3 region are directly involved in the interaction (11).
The structural insight into the complex between FVIII
and VWF presented by the recent three-dimensional struc-
ture (11,33) has provided novel and important information
about the VWF:FVIII complex. Although the negative stain
EM has contributed to the overall structure of the complex,
the nature of the current EM map and in particular its reso-
lution is such that residue-specific interactions cannot be
derived and flexible, yet imperative parts such as the FVIII
a3 region are absent in the EMmap. To understand the inter-
action between VWF and FVIII at a level where it can be
used to guide the developments of improved therapies for
patients with hemophilia A or VWD, more detailed infor-
mation is needed, specifically on the flexible FVIII a3 region
and its interaction with VWF.
Using a combination of NMR spectroscopy and
isothermal titration calorimetry (ITC), we present a charac-
terization of the interaction between VWF and FVIII with a
focus on the interactions mediated by the a3 region. Specif-
ically, we show a direct interaction between the FVIII a3 re-
gion and the VWF TIL’ domain and localize the affected
residues to two b-sheet regions on the VWF TIL’ domain.
Interaction Between FVIII and VWF TIL’E’It is also shown that VWF TIL’E’ binds to full-length FVIII
via the TIL’ domain and that this interaction is abrogated
when FVIII is activated and the FVIII a3 region is abscized.
Finally, mutations introduced in the VWF TIL’E’ domains
further highlight the importance of the b-sheet regions of
TIL’E’ for high-affinity binding.MATERIALS AND METHODS
Expression and purification of VWF TIL’E’
Four different constructs of VWF TIL’E’ were expressed and purified:
1) A gene coding for an enterokinase site (GTDDDDK) immediately
followed by residues 764–865 of VWF was cloned into a pET32b þ
expression vector with an N-terminal thioredoxin tag followed by a
His6 tag (GenScript, Hong Kong). This protein was expressed and puri-
fied essentially as described in (31), with the exception that the proteol-
ysis step to cleave off the thioredoxin- and His6-tag was carried out by
adding 1 mL 0.32 mg/mL enterokinase per 9 mg protein (New England
Biolabs, UK).
2) Expression and purification of the 15N-labeled VWF TIL’E’ domains
with an N-terminal mutation (GAMG followed by VWF residues
766–864) was carried out as detailed in (31).
3) Expression and purification of VWF TIL’E’ (residues 764–865) with a
C-terminal HPC4 purification tag (-ALAEDQVDPRLIDGK) was ob-
tained by preparing a construct with His6-DsbC-(G4S)2-enterokinase
site (DDDDK) immediately followed by a gene coding for residues
764–865 of VWF and the C-terminal HPC4 tag (EDQVDPRLIDGK)
preceded by a three-residue ALA-linker. This construct was cloned
into a pEt-11–derived expression vector and expressed in Escherichia
coli as detailed in (31). The purification procedure was initiated by son-
ication followed by homogenization in 20 mM Tris 150 mM NaCl
10 mM imidazole pH 8. The soluble fraction was applied to a NiNTA
column and eluted by increasing the concentration of imidazole. This
was followed by dialysis into 20 mM Tris 150 mM NaCl 10 mM imid-
azole pH 8 and subsequent cleavage of the N-terminal tag by addition of
enterokinase (1:5000, 4C overnight). The cleaved fraction was recov-
ered by applying the cleavage reaction to a NiNTA column and collect-
ing the flow-through. The final step of the purification was to apply this
to a 30Q anion exchange column and elute TIL’E’-ALA-HPC4 by
increasing the NaCl concentration. The correct molecular weight of
the protein was verified by mass spectrometry.
4) Unlabeled VWF TIL’E’ was expressed in HKB11 cell line (36,37).
Briefly, TIL’E’-ALA-HPC4 was purified by adding CaCl2 (final concen-
tration: 1 mM) to the medium and passing this over an anti-HPC4 col-
umn. The protein was eluted from the column using a buffer
containing 5 mM EDTA. The identity and purity of the TIL’E’ protein
was checked by Edman degradation analysis and sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis.
For constructs 1, 2, and 3, uniformly 15N-labeled samples were ob-
tained by protein overexpression in M9 medium with 1 g/L 15NH4Cl
(U-15N labeling) as the sole nitrogen source. For [U-15N,12C,2H; ILV
-13C1H3] isotope labeling, the protein was overexpressed in D2O based
M9 medium with 1 g/L 15NH4Cl and 3 g/L
12C D-Glucose-
1,2,3,4,5,6,6-d7. At an optical density at 600 nm of 0.5, the temperature
was lowered to 16C. After 15 min at 16C, 80 mg/L (2-keto-3-methyl-
d3-3-d1-1,2,3,4-
13C-butyrate) and 60 mg/L (2-keto-3,3-d2-1,2,3,4-
13C-
butyrate) precursors were added. One hour after the addition of the pre-
cursors, protein overexpression was induced by the addition of 500 mM
isopropyl-b-D-1-thiogalactopyranoside.
Due to their identical Kd for binding to full-length FVIII and their similar
15N-1H NMR spectra, constructs 1 and 3 were used interchangeably
throughout this study and generally referred to as VWF TIL’E’.VWD type 2N mutants
The VWD type 2N mutations R854Q and R854K were introduced into the
1 background by standard site-directed mutagenesis. The primers used
were 50-CGGTGCAGTTCCACTTCTGGTCACGGCAAACGCA-30 and
50-TGCGTTTGCCGTGACCAGAAGTGGAACTGCACCG-30. The VWD
type 2N mutation R816W was introduced into the 3 background.Peptide synthesis
The FVIII a3 peptides and analogs were synthesized by automated solid
phase peptide synthesis using the Fmoc/tBu strategy. Peptide syntheses
were performed on a 150 mmol scale using Fmoc amino acids. All reactions
were run under a nitrogen atmosphere at room temperature. Stock solutions
of Na-Fmoc protected amino acid solutions were prepared by dissolving
20 mmol amino acid in 58 mL 0.34 M Oxyma Pure in dimethylformamide
(DMF). Sulfated tyrosine residues were incorporated using neopentyl-
protected sulfotyrosine (Fmoc-Tyr(SO3nP)-OH) and were prepared by dis-
solving 600 mmol amino acid in 2 mL 0.34 M Oxyma Pure in DMF. A
coupling cycle was initiated by Fmoc deprotection with 20% (v/v) piperi-
dine in DMF (2  15 min) followed by wash with DMF (9). Fourfold
excess of the amino acid/Oxyma Pure solution was mixed with fourfold
excess of N,N-diisopropylcarbodiimide relative to resin loading, giving a
coupling concentration of 0.15 M. The solution was allowed to preactivate
for 10 min and was then added to the resin. Coupling proceeded for 1.5 h
and was agitated by sparging with nitrogen. The resin was then washed
with DMF (4) and the coupling cycle repeated.
At the end of the synthesis, the resin was washed with DMF (1) and
CH2Cl2 (6) followed by drying for 30 min. Finally, the peptides were
cleaved from the resin using a cleavage cocktail composed of trifluoroacetic
acid, H2O, and triisopropylsilane (95:2.5:2.5). Cleaved peptide solutions
were concentrated under a stream of nitrogen and precipitated and washed
with diethyl ether. The crude neopentyl-protected peptides were dissolved
in 2 M ammonium acetate, pH was adjusted to pH 8.5 with NH4OH, and
the solutions were stirred at 37C for 8 h. Purification was performed by
preparative high performance liquid chromatography on a Phenomenex
Gemini-NX C18 column using a linear gradient of 5–20% CH3CN in
10 mM NH4HCO3 over 40 min. The purified peptides were lyophilized
to yield colorless peptide ammonium salts.FVIII
For this study, B-domain deleted FVIII (N8, turoctocog alfa) (38) has been
used and is referred to as FVIII throughout. FVIII was activated by addition
of thrombin or using the CleanCleave Thrombin kit as detailed by the
manufacturer (Sigma-Aldrich, St. Louis, MO).NMR spectroscopy
All NMR spectra were recorded at 298 K on Bruker Avance III 700 MHz or
Bruker Avance III HD 800 MHz spectrometers equipped with cryoprobes.
NMR samples consisted of 10–300 mM isotope labeled TIL’E’ in 10 mM
HEPES 300 mM NaCl 5 mM CaCl2 5% D2O pH 7.3.
For the characterizations of the interaction between VWF TIL’E’ and
FVIII a3 peptides, lyophilized FVIII a3 peptide was dissolved to a final con-
centration of 500 mM directly into an NMR sample already containing
100 mM VWF TIL’E’. pH was subsequently adjusted to 7.3. For the char-
acterizations of the interaction between VWF TIL’E’ and FVIII, VWF
TIL’E’ was added to a concentration of 18 mM to a solution of 20 mMFVIII.
Two-dimensional 15N-1H heteronuclear single quantum correlation
(HSQC) spectra (39) were recorded with 3-9-19 Watergate, whereas
two-dimensional methyl–transverse relaxation optimized spectroscopy
(TROSY) experiments were recorded using the standard heteronuclear mul-
tiple quantum coherence pulse scheme (40).Biophysical Journal 117, 479–489, August 6, 2019 481
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Dagil et al.NMR data analysis
The nmrPipe/nmrDraw program package (41), CCPNmr Analysis version
2.4.2 (42), and FuDA (43) (https://www.ucl.ac.uk/hansen-lab/) were used
for processing and analyzing data. Chemical shift differences were calcu-
lated as Dd ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðDd1HÞ2 þ ð0:15Dd15NÞ2
q
.
An upper bound for the dissociation constant, Kd, between VWF TIL’E’
and the FVIII a3 peptides was estimated from the chemical shift changes
observed. From the small chemical shift changes observed between spectra
of 1) free VWF TIL’E’ and 2) VWF TIL’E’ in the presence of the FVIII a3
peptides, it can be assumed that the binding and dissociation reaction are in
the fast-exchange regime (44). In the fast-exchange regime, the observed
chemical shift in NMR spectra is given by the population-weighted average
of free and bound VWF TIL’E’. The change in chemical shift between free
VWF TIL’E’ and TIL’E’ in the presence of FVIII a3 therefore report on the
fraction of bound VWF TIL’E’. The possible range of amide 1H chemical
shifts is between 7 and 9.5 parts per million (ppm), whereas the range on
nonglycine 15N chemical shifts is between 107 and 132 ppm. The maximal
1H shift observed between free and bound TIL’E’ is 0.035 ppm (C821;
8.75 ppm) and the maximal 15N shift is þ0.36 ppm (N819; 114.5 ppm),
both in the presence of a3sTyr1664-sTyr1680. This leads to a population of
the bound state of VWF TIL’E’ of pbound > 0.02. In the experiments, the
concentration of TIL’E’ was 100 mM and the concentration of FVIII
a3sTyr1664-sTyr1680 was 500 mM, thereby leading to a Kd < (0.98  100 
498 mM)/(0.02  100 mM) ¼ 24.4 mMz 25 mM.dcITC
ITC experiments were performed on a MicroCal iTC200 (Malvern
Instruments, Malvern, UK) at 25C. All experiments were performed
with a total of 19 injections (the first injection 0.4 mL, the rest 2 mL),
with 120 s between each injection and an initial delay of 60 s. The reference
power was set to 6 mcal/s, and the syringe was stirred at 750 or 1000 Rpm
depending on the specifications of the syringe. The concentrations of pro-
teins used are specified in the figure legends.e f
FIGURE 2 NMR spectrum showing the interaction between VWF
TIL’E’ and FVIII a3. (a) Overlay of 15N-1H HSQC spectra of free VWF
TIL’E’ (black) and VWF TIL’E’ (100 mM) in the presence of five molar
equivalent a3sTyr1664-sTyr1680 (500 mM) (red). (b) Zoom of the boxed area
in (a) where cross peaks with significant chemical shift changes are anno-
tated. Both spectra were recorded at a temperature of 298 K. (c)–(f) Chem-
ical shift changes, Dd, observed in VWF TIL’E’ upon addition of five molar
excess of differently sulfated a3 peptides, (c) a3nonsulf, (d) a3sTyr1664, (e)
a3sTyr1680, and (f) a3sTyr1664-sTyr1680. The dashed line shows the average
chemical shift changes in the individual experiments and therefore indicates
the confidence level. The gray shaded graphs in the background are the
chemical shift changes observed for VWF TIL’E’ between pH 7.0 and
7.5. Any chemical shift changes that are smaller than the pH-induced chem-
ical shift changes are not considered significant. A primary binding region
around residue 820 is observed and secondary binding regions around res-
idues 770 and 795. To see this figure in color, go online.RESULTS AND DISCUSSIONS
Interaction between VWF TIL’E’ and FVIII a3
The acidic a3 region of FVIII (Fig. 1 a) is known to be
essential for mediating the high-affinity interaction between
VWF and FVIII (1,8,9,13–15); however, the mechanism by
which the FVIII a3 region mediates this interaction is
unknown. With the structure and NMR chemical shift
assignment of the VWF TIL’E’ domains (Fig. 1 b) now
available (31), it becomes possible to characterize possible
direct interactions between FVIII a3 and VWF TIL’E’ and
therefore possible to probe the mechanism by which the
a3 region mediates the interaction between FVIII and VWF.
Peptides representing the FVIII a3 region were used to
probe the interaction between FVIII a3 and VWF TIL’E’.
These peptides can be produced in relatively high amounts
and to a high homogeneity. Peptides can also be produced
to mimic different sulfation patterns of FVIII, thereby prob-
ing the importance of Tyr1680 sulfation in FVIII a3 for the
interaction with VWF. Four FVIII a3 peptides spanning res-
idues 1649–1689 of FVIII were synthesized with different
sulfation patterns on Tyr1664 and Tyr1680: a3nonsulf without
any sulfations, a3sTyr1664 with Tyr1664 sulfated, a3sTyr1680482 Biophysical Journal 117, 479–489, August 6, 2019with Tyr1680 sulfated, and a3sTyr1664-sTyr1680 with both
Tyr1664 and Tyr1680 sulfated.
NMR spectroscopy is well-suited to characterize low-
affinity protein complexes with dissociation constants, Kd,
up to the high millimolar range (45). Initial ITC experi-
ments, Fig. S1, showed that a possible interaction between
FVIII a3 and VWF TIL’E’ would be in the millimolar range.
The interaction between VWF TIL’E’ and the four FVIII a3
peptides was therefore probed using NMR spectroscopy.
NMR samples of uniformly 15N-labeled VWF TIL’E’ with
unlabeled FVIII a3 peptide in approximately five times
molar excess (see Materials and Methods) were prepared
and 15N-1H HSQC spectra were recorded and compared
with spectra of free VWF TIL’E’. Fig. 2, a and b show
a b
c d
FIGURE 3 Chemical shift changes observed upon FVIII a3 peptide-
binding shown on the structure of VWF TIL’E’ (Protein Data Bank
[PDB]: 2MHP). (a) Chemical shift changes,Dd, upon addition of five molar
excess of FVIII a3sTyr1664-sTyr1680 to VWF TIL’E’. Red colors show the res-
idues with the largest chemical shift changes, blue smallest changes, and
gray show residues where no data are available. (b) Chemical shift changes
shown on the secondary structure elements of VWF TIL’E’ localize these
changes to the periphery of the two b-sheets in the VWF TIL’ subdomain.
(c) Chemical shift changes, Dd, upon addition of five molar excess of FVIII
a3nonsulf to VWF TIL’E’. (d) Chemical shift changes from (c) shown on
the secondary structure elements of VWF TIL’E’. Residues for which the
chemical shift changes caused by a3 binding are smaller than the
pH-induced shift are colored blue. To see this figure in color, go online.
Interaction Between FVIII and VWF TIL’E’overlays of HSQC spectra of free VWF TIL’E’ and
VWF TIL’E’ in the presence of FVIII a3sTyr1680. In
Fig. 2, c–f, the chemical shift changes, Dd ¼ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðDdHÞ2 þ ð0:15 DdNÞ2
q
, between free VWF TIL’E’ and
VWF TIL’E’ in the presence of the FVIII a3 peptides are
shown. As seen in Fig. 2, the chemical shift changes are
in general small with Dd < 0.01 ppm for most of the resi-
dues. Residues in VWF TIL’E’ with Dd> 0.01 ppm include
Met771, Val772, Lys773, Cys792, Gln793, Leu809,
Glu818, Asn819, Cys821, Val822, Ala823, Asn825,
and Lys843, and the highest chemical shift changes
(Dd > 0.03 ppm) are observed for Val772, Asn819,
Cys821, and Val822 all located in the VWF TIL’ subdomain.
The majority of the peaks overlay well, thus indicating
that there are no major structural changes in VWF TIL’E’
upon interaction with FVIII a3. It is interesting to note
that a subset of peaks show significant chemical shift
changes. A change in chemical shifts in a structurally
defined region upon addition of a binding partner reports
on the site of interaction (46). These chemical shift changes
can originate from small conformational changes or from
electrostatics or ring-current effects. When the chemical
shift changes observed in Fig. 2 are mapped on the structure
of VWF TIL’E, they highlight two regions. For the residues
with Dd> 0:03 ppm, Val772 is located on the edge of the
b1-b2 sheet, and Asn819, Cys821, and Val822 are located
on the b4 strand (Fig. 3).
Because the chemical shift changes are generally small,
separate experiments were devised to verify that these shifts
are not simply due to small changes in the sample condi-
tions, such as pH and concentration of salts. Specifically, a
pH titration from pH 6.5 to 8 in steps of 0.5 pH unit and a
titration of the NaCl concentration from 100 to 250 mM
in steps of 50 mM were performed (Fig. S2). Significant
shifts were only observed in the pH titration, whereas no sig-
nificant shifts were observed in the titration with NaCl. The
chemical shift changes observed in the pH titration are taken
into account in the interpretation of the data (see Figs. 2
and 3). Thus, chemical shift changes that are smaller than
the pH-induced shift are not considered significant.
It is important to state that saturation could not be reached
in any of the titrations, and it is therefore not possible to
obtain an accurate value for the Kd between FVIII a3 and
VWF TIL’E’ from the NMR data. However, from the chem-
ical shift changes obtained, e.g. up to 0.035 ppm in the 1H
dimension and from the range of possible amide 1H chemi-
cal shifts (7–9.5 ppm), an upper bound for the Kd can be
estimated to Kd ( 25 mM (see Materials and Methods).
Interestingly, the addition of FVIII a3 peptides with
Tyr1680 sulfated (a3sTyr1664-sTyr1680 and a3sTyr1680) give
significantly larger chemical shift changes compared to
FVIII a3 peptides where Tyr1680 is not sulfated (a3nonsulf
and a3sTyr1664). The residue-specific chemical shift changes
caused by the different FVIII a3 peptides are proportional,thereby confirming that the chemical shift changes are due
to protein-peptide interactions (Fig. S3). The residue-
specific chemical shift changes increase by a factor of
1.66 5 0.09 when Tyr1680 is sulfated (Fig. S3), in accord
with previous accounts, showing that Tyr1680 sulfation
increases the binding affinity (15). In contrast, there is no
significant increase in the chemical shift changes when
Tyr1664 is sulfated (a factor of 1.035 0.05).
As a further control for the interaction between
FVIII a3 and VWF TIL’E’, the interaction between a
severe VWD type 2N mutation of VWF (R816W) and
FVIII a3sTyr1664-sTyr1680, was characterized. Arg816 is
located in the VWF TIL’ b3-b4 sheet (31), where the largest
chemical shift changes were observed (Figs. 2 and 3). Also,
it has previously been shown that full-length VWF R816W
does not bind FVIII in enzyme-linked immunosorbent
assays (25). To assess this, 15N-1H HSQC spectra of free
VWF TIL’E’ R816W and VWF TIL’E’ R816W in the
presence of five molar excess of FVIII a3sTyr1664-sTyr1680
were recorded, similar to the experiments in Fig. 2. A subsetBiophysical Journal 117, 479–489, August 6, 2019 483
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FIGURE 4 NMR spectra of VWF TIL’E’ in the presence of FVIII
localize the interaction site to the N-terminal VWF TIL’ domain. (a)
15N-1H NMR correlation spectrum showing free VWF TIL’E’ (black)
and VWF TIL’E’ (18 mM) in the presence of molar excess (20 mM) of FVIII
(red). (b) 13C-1H NMR methyl-TROSY correlation spectrum showing free
VWF TIL’E’ (black) and VWF TIL’E’ (18 mM) in the presence of molar
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484 Biophysical Journal 117, 479–489, August 6, 2019of peaks within VWF TIL’E’ R816W was slightly affected
upon addition of FVIII a3sTyr1664-sTyr1680 (Fig. S4). How-
ever, the most affected residues are located far from each
other on the three-dimensional structure of VWF TIL’E’.
In addition, the chemical shift changes observed for VWF
TIL’E’ R816Ware substantially smaller than those observed
for wild-type VWF TIL’E’ in the presence of FVIII
a3sTyr1664-sTyr1680, thereby substantiating that the b3- b4
sheet is important for interaction and that the R816W muta-
tion decreases the affinity between FVIII a3 and VWF
TIL’E’.Interaction between FVIII and VWF TIL’E’
Binding experiments with FVIII, as opposed to just the a3
region, were performed to further characterize the interac-
tion between VWF and FVIII. The addition of substoichio-
metric amounts (1:3) of FVIII to a sample of 15N-labeled
VWF TIL’E’ did not lead to chemical shift changes of the
VWF TIL’E’ cross peaks in 15N-1H HSQC spectra; instead,
it led to a change in the peak intensities vide infra. This
observation shows that the exchange between bound and
free TIL’E’ is in the intermediate to slow-exchange regime
(44,47), meaning that the dissociation rate of the TIL’E’:
FVIII complex is slower than the chemical shift differences
(rad/s) between the peaks of free and bound VWF TIL’E’.
The effect of binding was therefore characterized using
two samples, a sample with ‘‘free’’ 15N-labeled VWF
TIL’E’ and a sample with ‘‘bound’’ VWF TIL’E’ made by
adding a slight molar excess of unlabeled FVIII. A 15N-1H
HSQC spectrum of bound VWF TIL’E’ is compared to
free VWF TIL’E’ in Fig. 4 a.
A total of 94 peaks are theoretically possible for the VWF
TIL’E’ construct in 15N-1H HSQC spectra; however, in
the spectrum of the VWF TIL’E’:FVIII complex, only
30 peaks are observed. The VWF TIL’E’ peaks observed
in the 15N-1H HSQC spectrum of the complex originate pri-
marily from the VWF E’ domain, and the peak intensities
vary substantially over the structure (Fig. 4 c), with the
peaks from residues in VWF TIL’ being most reduced.
Reduced intensity of peaks in the spectrum is the result of
line-broadening caused by the large size of the complex
(180 kDa) and chemical exchange between a bound andexcess (20 mM) of FVIII (red). For both (a) and (b), a subset of the cross
peaks that disappear upon complex formation with FVIII are encircled
and denoted in black writing, whereas a subset of the cross peaks that are
visible in both free and complexed form of VWF TIL’E’ are encircled
and denoted in red writing. (c) Residue-specific intensity ratios, Icomplex/
Ifree, colored on the structure of VWF TIL’E’ (PDB: 2MHP). The intensity
ratios are calculated from the intensity of the respective cross-peak in the
15N-1H spectrum of free VWF TIL’E’ (Ifree) and the cross peaks in the
15N-1H spectrum of VWF TIL’E’ in the presence of molar excess of FVIII
(Icomplex). Side chains circled in (b) are shown as sticks colored black
for peaks that disappear and red for peaks that are visible in the 13C-1H
spectrum. To see this figure in color, go online.
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Interaction Between FVIII and VWF TIL’E’unbound state, albeit on a timescale that is not suited for
NMR spectroscopy. To further characterize the interaction,
an alternative labeling strategy was employed. NMR spec-
troscopy of proteins with selectively isotope labeled
13C1H3-methyl groups in a completely deuterated back-
ground has emerged as an eminent technique to probe large
macromolecular complexes due to the favorable relaxation
properties of the methyl groups (48,49). Therefore, specific
13C1H3-labeling of isoleucine
13Cd1, valine 13Cg1, 13Cg2,
and leucine 13Cd1, 13Cd2 of VWF TIL’E’ was employed.
VWF TIL’E’ has a total of 16 Ile, Leu, and Val residues
evenly distributed over the structure, theoretically giving
rise to 31 methyl peaks in a 13C-1H methyl-TROSY experi-
ment (50). In the spectrum of 13C1H3 Ile, Leu, and
Val labeled VWF TIL’E’ 29 peaks are distinguishable
(Fig. 4 b). The chemical shifts of these peaks have previ-
ously been stereospecifically assigned (31). When adding
a slight molar excess of FVIII to VWF TIL’E’, the majority
of the methyl peaks in the N-terminal VWF TIL’ domain
disappears. This supports the results obtained above,
showing that primarily VWF TIL’ is affected by the interac-
tion with FVIII. Even though this labeling scheme is optimal
for large proteins and complexes, the method is dependent
on per-deuteration of all sites near the observed methyl
groups. FVIII is produced in mammalian cell lines and as
such a fully deuterated sample of FVIII could not be ob-
tained. Many of the methyl groups of Leu and Val residues
in VWF TIL’ are surface exposed, and the disappearance of
peaks in the methyl-TROSY spectra is therefore most likely
caused by the rapid relaxation caused by the 1H in FVIII.
The low concentration of the sample precluded a more
quantitative characterization of the binding kinetics. Despite
these difficulties, this experiment still underlines that the re-
gion most involved in complex formation with FVIII is
VWF TIL’ in agreement with the titration of FVIII a3 shown
above (Fig. 3 c).FIGURE 5 ITC experiment showing binding between VWF TIL’E’ and
FVIII. (a) Representative ITC experiment showing the binding between
VWF TIL’E’ and FVIII. Three independent ITC experiments were used
to obtain the thermodynamic parameters and their uncertainties: Kd ¼
0.71 5 0.26 mM, N ¼ 1.0 5 0.3, DH ¼ 12.0 5 1.3 kcal/mol. (b) ITC
experiment showing substantially reduced binding between the VWF
TIL’E’ construct with the additional N-terminal glycine and alanine resi-
dues, VWF GAMG-TIL’E’, and FVIII. (c) Substantially reduced binding
between VWF R816W TIL’E’ and FVIII. (d) Weak binding between
VWF R854Q TIL’E’ and FVIII: Kd ¼ 7.2 5 0.6 mM, N ¼ 1.29 5 0.03,
DH ¼ 7.55 0.2 kcal/mol (one run).Perturbing the interaction between FVIII and VWF
TIL’E’
VWD type 2N mutations are already known to cause struc-
tural perturbations of VWF (51) that lead to a reduced
VWF:FVIII binding affinity, and mapping these mutations
onto the three-dimensional structure of VWF TIL’E’ has
already provided insight into the FVIII binding region on
VWF (31). From the experiments above, it is clear that
the N-terminal VWF TIL’ subdomain and the FVIII a3 re-
gion play important roles for the interactions between
VWF and FVIII. To characterize the interaction between
FVIII and VWF TIL’E’ further, FVIII was activated by
thrombin, during which the FVIII a3 region is cleaved off.
As seen in Fig. S5, the spectrum of VWF TIL’E’ in the pres-
ence of FVIII, but upon thrombin activation of FVIII and
production of activated FVIII, is identical to the spectrum
of free VWF TIL’E’. Therefore, activation of FVIII andcleaving off FVIII a3 leads to a dissociation of the complex
between FVIII and VWF. Thus, as shown previously (8), the
FVIII a3 region is important for high-affinity binding be-
tween VWF TIL’E’ and FVIII. Furthermore, this experi-
ment supports that the disappearance of VWF TIL’ peaks
in the NMR spectrum of the VWF TIL’E’:FVIII complex
is caused by an interaction between FVIII and VWF TIL’E’.
The dissociation constant for the VWF TIL’E’:FVIII
complex is 0.7 5 0.3 mM from ITC experiments
(Fig. 5 a), whereas the dissociation constant for the VWF
TIL’E’:FVIII a3 complex was estimated above to be
<25 mM. The FVIII a3 region therefore contributes aboutBiophysical Journal 117, 479–489, August 6, 2019 485
Dagil et al.one-third of the binding free energy for the formation of the
VWF TIL’E’:FVIII complex. Dissociation of the VWF
TIL’E’:FVIII complex upon activation by thrombin is in
agreement with the determined dissociation constants. It
should be noted, however, that the FVIII a3 region could
sample different conformations in isolation and covalently
bond to the FVIII A3 domain, which could alter its contribu-
tion to the binding energy.
Mutations were made in the VWF TIL’E’ regions that
showed chemical shift changes upon interaction with FVIII
a3. Chemical shift changes are observed in the b1-b2 region
upon FVIII a3 binding to VWF TIL’E’ and previous studies
have emphasized the importance of the native N-terminus of
mature VWF in mediating the binding to FVIII. These
include that the addition of an N-terminal alanine residue
abolishes binding (52,53). A construct of VWF GAMG-
TIL’E’, corresponding to the four amino acids GAMG
followed by residues 766–864 of VWF, TIL’ was conve-
niently available to this study and expresses well in
E. coli. Importantly, the GAMG-TIL’E’ construct has an
additional alanine residue in position 763, which was previ-
ously shown to abolish binding to FVIII, as well as a glycine
in position 762. An ITC experiment on the VWF GAMG-
TIL’E’ construct confirmed that the binding to FVIII had
been abrogated (Fig. 5, a and b) by the additional amino
acids. The VWF GAMG-TIL’E’ construct was further char-
acterized using two-dimensional 15N-1H HSQC spectra to
deduce the origin of the decrease in binding affinity. Specif-
ically, a comparison of the spectrum of the wild-type
construct, VWF TIL’E’, and the VWF GAMG-TIL’E’
construct with the additional alanine residue, showed very
few differences in chemical shifts and peak intensities
(Fig. S6). Three residues had chemical shift differences
significantly larger than the mean chemical shift difference
(hDd i) of 0.04 ppm; these were Lys773, Cys808, and
Leu809 (hDd i 0.06–0.12 ppm). As such, the structural
and dynamical differences caused by the additional N-ter-
minal glycine and alanine residues are minor; yet, the
b1-b2 sheet is perturbed. Consequently, the lower binding
affinity of VWF GAMG-TIL’E’ is not due to overall struc-
tural perturbations but is most likely caused by a local
perturbation to the b1-b2 region. Two control constructs
were produced. The first construct had 15 additional C-ter-
minal residues (-ALAEDQVDPRLIDGK), corresponding
to a HPC4 purification tag that was not cleaved off, which
did not affect the binding between VWF TIL’E’ and FVIII
(Kd ¼ 0.64 5 0.16 mM). The second control construct
was expressed in a mammalian cell line, which also did
not affect the binding (Kd ¼ 0.755 0.25 mM) and resulted
in an 15N-1H HSQC spectrum similar to VWF TIL’E’ pro-
duced in bacterial cells (Fig. S7). Of the peaks present,
only small chemical shift changes were observed between
VWF TIL’E’ produced in bacterial cells and VWF TIL’E’
produced in mammalian cells. The good agreement between
peak position and relative peak intensity of the two spectra486 Biophysical Journal 117, 479–489, August 6, 2019show that correct folding and disulfide bridge formation is
achieved from bacterial E. coli expression.
Mutations in the b3-b4 sheet region of VWF TIL’E’ are
already known to abrogate VWF:FVIII binding. For
example, the severe type 2N mutation R816W is located
in the VWF TIL’ b3-b4 sheet (31). As expected, no binding
was observed between FVIII and VWF TIL’E R816W in
ITC experiments (Fig. 5 c). To further characterize this
mutant and the cause of its impaired FVIII binding, a
15N-1H HSQC spectrum was recorded, and the chemical
shift changes between VWF R816W TIL’E’ and wild-type
VWF TIL’E’ were quantified (Fig. 6 a). The effect of intro-
ducing the R816W mutations is observed near the site of the
mutation in the VWF TIL’ domain (Fig. 6 a), in the b3-b4
b-sheet (residues 814–824), and in the region where VWF
TIL’ and E’ interacts (residues 792–795).
The type 2N mutant R854Q, which leads to a mild pheno-
type VWD, is located in the E’ domain, and it was previ-
ously not clear how this mutation affects the VWF:FVIII
binding. The R854Q mutation leads to an increase in Kd
(Kd ¼ 7.2 5 0.6 mM) by about an order of magnitude
compared to the wild-type (Fig. 5 c), and R854K leads to
a more than 20-fold increase in Kd (Kd ¼ 25 5 20 mM)
as shown by ITC experiments. As above, two-dimensional
15N-1H HSQC spectra and chemical shift changes between
VWF R854Q/K TIL’E’ and wild-type VWF TIL’E’ were
used to probe a possible mechanism. Although the R854Q
and R854K mutations are located in the VWF E’ domain,
both of these mutations lead to significant chemical shift
changes in the VWF TIL’ domain, and, importantly, the
chemical shift changes coincide with the regions that are
affected by FVIII a3 binding (Fig. 6, b and c). One possible
route by which the R854Q/K mutations decrease the affinity
of TIL’E’ for FVIII is therefore due to an allosteric pertur-
bation of the b1-b2 and b3-b4 b-sheets of the VWF TIL’
domain. In that regard, it is interesting to note that the
R854K mutation, which preserves charge, leads to a larger
(allosteric) perturbation in the b-sheets of the VWF TIL’
domain and a weaker FVIII binding affinity.CONCLUSIONS
It has previously been suggested that the FVIII a3 region is
responsible for mediating high-affinity binding to VWF, and
although it was known that the tyrosine sulfation pattern of
the FVIII a3 region affects the VWF:FVIII binding affinity,
the mechanism by which the FVIII a3 region stabilizes the
VWF:FVIII interaction was not known. Significant chemi-
cal shift changes in NMR spectra of VWF TIL’E’ were
observed upon addition of FVIII a3 peptides, which shows
a direct interaction between VWF TIL’E’ and the FVIII
a3 region, albeit with millimolar affinity. The chemical shift
changes are observed near the two b-sheets of the VWF TIL’
subdomain (b1-b2 and b3-b4). The micromolar interaction
between VWF TIL’E’ and FVIII was further characterized
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FIGURE 6 Mapping chemical shift changes between wild-type VWF
TIL’E’ and the type 2N mutants R816W and R854Q as well as R854K.
(a) Chemical shift changes, Dd, between wild-type and R816W. (b) Chem-
ical shift changes, Dd, between wild-type and R854Q. (c) Chemical shift
changes, Dd, between wild-type and R854K. The secondary structure
elements are shown above the plot and the dashed line shows the border
between the VWF TIL’ and E’ domains. The areas significantly affected
by the interaction with FVIII a3sTyr1664-sTyr1680 are shaded red. The red
X denotes the site of mutation in each panel. To see this figure in color,
go online.
Interaction Between FVIII and VWF TIL’E’using NMR and ITC. Firstly, activated FVIII that lacks the
a3 region does not interact with VWF TIL’E’. Secondly,
mutations to VWF TIL’E’ that perturb the two b-sheets in
VWF TIL’, b1-b2 and b3-b4, destabilize the interaction be-
tween VWF TIL’E’ and FVIII. Specifically, a construct with
just two additional N-terminal amino acids, VWF GAMG-
TIL’E’, leads to chemical shift changes in the b1-b2 region,
and this construct is unable to bind FVIII with micromolar
affinity. Additional mutants of VWF TIL’E’ that have alower affinity for FVIII also show chemical shift changes
in the two b-sheets. Two of these mutants (R854K/Q) are
distant to the b1-b2 and b3-b4 b-sheets, but the mutations
still lead to chemical shift changes in the region where FVIII
a3 interacts.
Characterizing the complex between VWF and FVIII is
crucial for deducing the molecular functions of these
proteins to increase our understanding of the molecular
basis for bleeding diatheses, such as VWD and hemophilia
A. The complex between VWF and FVIII has therefore
attracted substantial attention over the last decades
(7,19–22). The recent three-dimensional structures of the
VWF TIL’E’ domains (31), the TIL’E’D3 module (32),
and the FVIII:TIL’E’D3 complex (11,33) have provided
the necessary platform to interpret the findings above in
a structural context. The localization of the binding site
of the FVIII a3 on VWF TIL’E’ to the b-sheet region of
VWF TIL’ provides an important step toward a high-reso-
lution structural characterization of the complex between
VWF and FVIII and a detailed molecular understanding
of this essential complex in biology and in bleeding
disorders.SUPPORTING MATERIAL
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